<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03430505</url>
  </required_header>
  <id_info>
    <org_study_id>OEP Asthma</org_study_id>
    <nct_id>NCT03430505</nct_id>
  </id_info>
  <brief_title>Effects of Noninvasive Ventilation Compared to Salbutamol</brief_title>
  <official_title>Effects of Noninvasive Ventilation Compared to Salbutamol in Respiratory Mechanics and Lung Function of Asthmatics After Bronchoprovocation: Randomized Cross-over Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Nove de Julho</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Nove de Julho</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Asthma is a chronic inflammatory disease characterized by recurrent and reversible episodes&#xD;
      of airway obstruction. Drug treatment usually includes inhaled corticosteroids and bronchial&#xD;
      dilators, which often do not have adequate adherence. These acute episodes of&#xD;
      bronchoconstriction can most often occur with hyperinflation and for decades the mechanisms&#xD;
      that lead to hyperinflation have been studied, as well as increasingly modern ways of&#xD;
      evaluating and treating these mechanisms. Noninvasive ventilation is increasingly occupying&#xD;
      its space as a non-pharmacological resource in the treatment of asthma, initially as an&#xD;
      adjunct in an attempt to help medication have its effect reached in the crisis, but this&#xD;
      feature has been showing signs of having an even greater action which can even collaborate in&#xD;
      reversing the crisis by not only giving time for pharmacological action. Recognizing these&#xD;
      potential effects of this widely used resource and understanding its action on lung function&#xD;
      and the reversal of exacerbation is part of this scientific process.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Asthma is a chronic inflammatory disease characterized by recurrent episodes of reversible&#xD;
      airway obstruction. The drug treatment typically includes inhaled steroids and bronco&#xD;
      dilators. These acute episodes of bronchoconstriction can, for the most part, attend with&#xD;
      hyperinflation, the hyperinflation and the consequent increase of functional residual&#xD;
      capacity (FRC) inspiratory muscle activation in phase before the expiratory lung elastic&#xD;
      equilibrium and rib cage.&#xD;
&#xD;
      Some studies reports the injury to respiratory function that causes acute hyperinflation with&#xD;
      a reduction of the contribution of the abdominal compartment and increased assistance from&#xD;
      the chest compartment, thereby reducing the efficiency mechanics of the diaphragm in response&#xD;
      to decreased your stamping area. As a result of this disadvantage and mechanics &quot;reduction of&#xD;
      curvature&quot; of the diaphragm expiratory muscle activation occurs in an attempt to restore the&#xD;
      original mechanics and thus your primary function.&#xD;
&#xD;
      Some studies have investigated the effects of bronchoconstriction in recruitment of the&#xD;
      respiratory muscles and respiratory mechanics of patients susceptible to asthma. As asthma&#xD;
      has distinct characteristics in crisis and in stable phase, testing of bronchial provocation&#xD;
      test have been part of the studies allowing assessment in different physiological conditions,&#xD;
      close to an acute condition without necessarily a crisis and insufficiency that would make it&#xD;
      really an assessment respiratory kinematics and the involvement of the thoracic and abdominal&#xD;
      compartments in each of these phases and mainly in front of any therapy.&#xD;
&#xD;
      Bronchial provocation tests are safe once they cause the release of endogenous mediators that&#xD;
      cause the bronchial smooth muscle contraction causing narrowing of the airway, but as your&#xD;
      sensitivity is reduced your action is completely reversed with use of bronchodilator and the&#xD;
      positive response to these tests that can be performed by exercise or inhaling hypertonic&#xD;
      solution 4.5% reflect a inflammation of the Airways.&#xD;
&#xD;
      The interest in the implementation of non-pharmacological therapies and especially the&#xD;
      knowledge of resources used often to relieve the overload of respiratory muscles in patients&#xD;
      with obstructive, since the Decade of 80, has been demonstrating that the use of expiratory&#xD;
      positive pressure can reduce muscle work and reduce the volume of expiratory reserve&#xD;
      contributing to deflation.&#xD;
&#xD;
      Most recently the bronchodilator effect of CPAP mediated by autonomic receptors stretch lung.&#xD;
      What we need to know is the effect of non-invasive ventilation with two levels of pressure&#xD;
      can in addition to trigger this neural reflex, can still promote a kinematics similar to&#xD;
      produced by bronchodilator seen through optoelectronics plethysmography (OEP).&#xD;
&#xD;
      The Optoelectronics Plethysmography (OEP) has made possible the exploitation of&#xD;
      Thoracoabdominal movement by magazines, reporting especially changes in total volume of the&#xD;
      chest wall during any intervention as the NIV.&#xD;
&#xD;
      The OEP is an innovative method of indirect measurement of pulmonary ventilation, and your&#xD;
      application can be used in different health conditions, like asthma and neuromuscular&#xD;
      diseases, with different protocols. Is a non-invasive method and measurement of non-ionizing&#xD;
      lung volumes, able to detect small movements of the chest wall during breathing through the&#xD;
      analysis of reflective markers attached to the chest wall of the individual; There is no need&#xD;
      to use mouthpiece, nasal clip or other connector of the equipment to the individual; the&#xD;
      calibration is fast and without the participation of the subject.&#xD;
&#xD;
      Since the NIV with bi-level pressure promotes a level of inspiratory pressure that increases&#xD;
      the expiratory ventilation and a stretch of lung receptors stimulates and bronchodilator&#xD;
      effect, the hypothesis of this study is that the thoracic and abdominal configuration and&#xD;
      improvement of pulmonary function after test of bronchial provocation test is considerable&#xD;
      with the NIV compared to bronchodilator. There are no studies in the literature that discuss&#xD;
      this subject under this optics of assessment.&#xD;
&#xD;
      The aim of this study is to evaluate the effects of the NIV in reversal of bronchial&#xD;
      provocation test and your potential bronchodilator effect compared to the gold standard&#xD;
      bronchodilator drug seen by thoracic and abdominal and lung function configuration.&#xD;
&#xD;
      2. General Purpose&#xD;
&#xD;
      To evaluate the responses of the thoracoabdominal configuration and the participation of the&#xD;
      thoracic and abdominal compartments in asthmatic patients before the bronchoprovocation test&#xD;
      and in response to pharmacological and non-pharmacological therapy.&#xD;
&#xD;
      2.1. Specific objectives&#xD;
&#xD;
        -  To evaluate the abdominal thoracic configuration of adolescents and young adults with&#xD;
           stable asthma before and after bronchoprovocation&#xD;
&#xD;
        -  To evaluate the effect of bronchodilator and NIV in the thoraco-abdominal configuration&#xD;
&#xD;
           3. Materials and Methods&#xD;
&#xD;
      3.1. Kind of study&#xD;
&#xD;
      This is a randomized, crossover clinical trial in which it will be performed in two visits&#xD;
      and evaluated the abdominal thoracic configuration before and after bronchoprovocation and&#xD;
      after bronchodilator and non-invasive ventilation (NIV) with two levels of pressure in&#xD;
      adolescents and young adults with asthma.&#xD;
&#xD;
      3.2. Ethical aspects&#xD;
&#xD;
      This study will be developed respecting the research standards involving human beings&#xD;
      (Resolution CNS 466/2012) of the National Health Council, was approved by the Research Ethics&#xD;
      Committee of the University Nove de Julho (2.130.007 / 2017). You will have your registration&#xD;
      done at clincaltrial.gov.&#xD;
&#xD;
      3.3. Place of study and sample&#xD;
&#xD;
      The study will be developed in the Multidisciplinary Laboratory of Movement, Optical&#xD;
      Electronic Plethysmography (OEP) and in the Functional Respiratory Evaluation Laboratory&#xD;
      located at the Latin American Memorial Campus of the University of Nove de Julho (UNINOVE),&#xD;
      at Francisco Matarazzo Avenue, 376, Barra Funda , Sao Paulo-SP.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 10, 2017</start_date>
  <completion_date type="Actual">December 20, 2018</completion_date>
  <primary_completion_date type="Actual">July 11, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>FEV1</measure>
    <time_frame>Change from baseline FEV1 at 1 hour</time_frame>
    <description>Spirometry</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Expiratory time</measure>
    <time_frame>Change from baseline expiratory time at 1 hour</time_frame>
    <description>Optoeletronic Plethismography</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Inspiratory Capacity</measure>
    <time_frame>Change from baseline IC at 1 hour</time_frame>
    <description>Spirometry</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Minute Volume</measure>
    <time_frame>Change from baseline minute volume at 1 hour</time_frame>
    <description>Optoeletronic Plethismography</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Bilevel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bilevel 10 minutes after bronchoprovocation with saline solution 4.5%. IPAP 12 and EPAP 8</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Albuterol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>400micrograms after bronchoprovocation with saline solution 4.5%.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Bilevel</intervention_name>
    <description>Basal respiratory mechanics in spontaneous breathing will be analyzed by optoeletronic plethismography (OEP), followed by bronchial provocation with hypertonic saline solution 4.5%, another 45-second OEP uptake, IPAP 12 and EPAP 8 bilevel applied for 10 minutes, and a new uptake. All abstractions are preceded by a forced and slow spirometry maneuver. The entire procedure takes 1 hour.</description>
    <arm_group_label>Bilevel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Albuterol</intervention_name>
    <description>Basal respiratory mechanics in spontaneous breathing will be analyzed by optoeletronic plethismography (OEP), followed by bronchial provocation with hypertonic saline solution 4.5%, another 45-second OEP uptake, 400 micrograms inhaled Albuterol, and a new uptake. All abstractions are preceded by a forced and slow spirometry maneuver. The entire procedure takes 1 hour.</description>
    <arm_group_label>Albuterol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA:&#xD;
&#xD;
          -  Age 12 to 29 years&#xD;
&#xD;
          -  Both sexes&#xD;
&#xD;
          -  Diagnosis of asthma according to GINA&#xD;
&#xD;
          -  Without deterioration in the last 30 days&#xD;
&#xD;
          -  No history of respiratory infection in the last 2 months&#xD;
&#xD;
          -  Comply with consent form&#xD;
&#xD;
        EXCLUSION CRITERIA:&#xD;
&#xD;
          -  Use bronchodilator under 12 hours&#xD;
&#xD;
          -  No understanding of the tests&#xD;
&#xD;
          -  Heart condition&#xD;
&#xD;
          -  Intolerance the proposed activities&#xD;
&#xD;
          -  Don't have bronchodilator prescribed by doctor&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>29 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dirceu Costa, Doctor</last_name>
    <role>Study Chair</role>
    <affiliation>Nove de Julho University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nove de Julho University</name>
      <address>
        <city>SÃ£o Paulo</city>
        <zip>01.504-001</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>January 31, 2018</study_first_submitted>
  <study_first_submitted_qc>February 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 13, 2018</study_first_posted>
  <last_update_submitted>July 18, 2019</last_update_submitted>
  <last_update_submitted_qc>July 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Nove de Julho</investigator_affiliation>
    <investigator_full_name>Evelim Leal de Freitas Dantas Gomes, PT</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>Asthma, noninvasive ventilation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Albuterol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

